Northland Capital Partners Limited Morning Report: Evgen Pharma PLC

Final patient recruited in the STEM Phase IIa trial

NORTHLAND VIEW

  • Evgen Pharma announced that it has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.
  • STEM is an open label trial that had regulatory approval to recruit 60 patients. Following the favourable interim read-out announced on 11th June 2018, the Principal Investigator and the Company’s medical adviser believe there is now sufficient evidence to conclude that the main aims of the trial, being that of a strong safety and tolerability profile together with evidence of clinical benefit, have been successfully met. On this basis, the Company has decided that there is no merit in recruiting the full number of patients allowed under the protocol. As at 24th July 2018, 50 patients had been enrolled in the trial although any eligible patients currently in screening will also be admitted to the trial.
  • All eligible patients will continue as per the trial protocol, receiving SFX-01 until such point as they show clinical progression or reach the end of the 6 month trial. If they receive clinical benefit for the full duration of the trial, as have all other patients in the trial, they will be eligible for entry into the compassionate use programme.

This is a very positive result. The STEM trial data appears to support further clinical evaluation of STX-01. The final readout should occur around the end of 2018E, providing details of the safety, tolerability and the clinical benefit rate observed across all patients. Subject to this confirming evidence to date, the next step is likely to be a placebo-controlled trial, testing SFX-01 in combination with second-line hormone therapy in patients that have failed on CDK4/6 inhibitors. This is the initial setting for which management aims to target SFX-01’s approval in metastatic breast cancer.

COMPANY DESCRIPTION

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Evgen Pharma Plc

    More articles like this

    Evgen Pharma Plc

    21 Health Benefits of Broccoli

    Are you looking for a vegetable to spice up your diet in a healthy way? If yes, then broccoli, also called Brassica oleracea italica, is the vegetable you want. The dark green crucifer is not only

    Evgen Pharma Plc

    12 things that are actually tied to breast cancer

    According to the Centres for Disease Control and Prevention (CDC), breast cancer is the most common cancer in women. In the US, one in eight women will develop breast cancer during her lifetime. Those statistics sound

    Evgen Pharma Plc

    10 subtle signs of breast cancer

    A diagnosis of breast cancer can be terrifying. According to the CDC, Breast cancer is the most common cancer in American women of any race or ethnicity. Though the statistics might be scary, catching breast cancer

    Evgen Pharma Plc

    Evgen Pharma plc Investor Presentation in Manchester

    Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that Steve Franklin, the Company’s CEO, will be presenting tomorrow evening at a ShareSoc Growth

    Evgen Pharma Plc

    ‘I never knew men could get breast cancer’

    Moses Musonga never thought men could get breast cancer until he was diagnosed with the disease in 2013. The 67-year-old Kenyan told the BBC that he was profoundly shock when doctors told him in 2013 that

    Evgen Pharma Plc

    Male Breast cancer:What are the signs and how to check?

    Breast cancer is more commonly associated with women more than with men, affecting approximately one in eight women in their lifetimes. However, men can still be diagnosed with breast cancer, albeit in far rarer circumstances. While